DENVER, Sept. 08, 2025 (GLOBE NEWSWIRE) -- GrowGeneration Corp. (NASDAQ: GRWG) (“GrowGen” or the “Company”), the nation’s largest specialty hydroponic and organic gardening retailer, today announced that Darren Lampert, GrowGen’s Chief Executive Officer and Co-Founder, will present virtually at the H.C. Wainwright 27th Annual Global Investment Conference, which is being held September 8-10, 2025 in New York City. Mr. Lampert’s presentation is now available on demand in the Investor Relations section of the ...

WASHINGTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced the appointment of Ralph L. Hunter, Jr. to the board of directors of ASP Isotopes and the board of managers of Quantum Leap Energy LLC. Ralph L. Hunter, Jr. has over thirty years' experience in the nuclear power industry in leadershi ...

NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Aeries Technology, Inc. (NASDAQ: AERT), a global leader in AI-powered business transformation and Global Capability Center (GCC) services, today recapped a strong first eight months of 2025, highlighting record quarterly performance, strategic leadership realignment, platform-led AI innovation, and aggressive global expansion. January–March 2025: Leadership Realignment to Sharpen Focus In February, Aeries underwent a strategic leadership transition. Ajay Khare wa ...

The leading European asset manager specializing in digital assets with ~US$10 billion in AuM sets sights on expanding into U.S. market CoinShares ranks among the top four managers globally by crypto ETP AuM alongside BlackRock, Fidelity, and Grayscale and holds the #1 market position in Europe with 34% market share CoinShares is experiencing a period of significant growth; AuM has more than tripled over the last two years through strong investor inflows, supportive digital asset pricing and successful new p ...

Data to be presented in the Immunotherapy & Cell Therapy in Sarcoma: Emerging Frontiers session at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting SYDNEY, AUSTRALIA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an abstract for the EFTISARC-NEO Phase II investigator-initiated trial has been accepted for oral presentation at the Connectiv ...

On 5 May 2025, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 20 of 2 May 2025. Under the programme, Schouw & Co. will acquire shares for up to DKK 120 million during the period 5 May to 31 December 2025. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules). Tr ...

Seasoned industry leader to strengthen company’s strategic engagement and policy voice in Medicare AdvantageORANGE, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC) today announced that Matt Eyles will join as executive vice president of government and business strategy, effective Sept. 29. In this newly created position, Eyles will report directly to Alignment founder and CEO John Kao, elevating Alignment’s engagement and leadership in health care policy at federal and s ...

Company remains in good standing on Nasdaq Capital Market; strengthens platform to execute commercialization and growth strategyRENO, Nev., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Aqua Metals, Inc. (NASDAQ: AQMS), a leader in sustainable lithium battery recycling, today announced that it has received written notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Capital Market and that the m ...

FDA alignment on Phase 3 ozuriftamab vedotin (Oz-V) trial design, including dosing regimen and endpoints to support potential accelerated approvalCompany continues preparations for enabling initiation of the Phase 3 study with the goal of advancing the study with a strategic partner early next yearCompany maintains previous guidance for completion of a strategic partnership with one of our advanced clinical assets this year SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global ...

BOSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing treatments for neurological disorders and neuro-oncology, and a subsidiary of Beyond Air (NASDAQ: XAIR), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead investigational therapy, BA-101, for the treatment of Glioblastoma (GBM). GBM is an aggressive primary brain tumor with limited treatment options and poor prognosis under current standa ...